Global Next Generation Sequencing Services Market 2026 – 2035

The market size of the global next generation sequencing services will be estimated at USD 6.8 billion in 2025 and is expected to grow to between USD 8.3 billion in 2026 and about USD 56.1 billion by 2035 with a current CAGR of 23.5% during the period of 2026 to 2035. The main drivers of the next-generation sequencing service market are the drastic fall of sequencing prices along with the constant improvements of sequencing technologies that have made large-scale genomic analysis for research institutions, hospitals, and biotech companies more viable and more affordable.

Besides, NGS adoption in cancer treatment, rare disease diagnosis, reproductive health, and infectious disease testing is a major factor increasing the demand for outsourced sequencing services since many healthcare providers lack the necessary setup or know-how to conduct the tests in-house. Conversely, pharmaceutical and biotech companies are progressively outsourcing entire sequencing projects for drug discovery, biomarker detection, companion diagnostics, and clinical trials to save on capital investment and time. Additionally, government and public health initiatives in the fields of population genomics, pathogen surveillance, and precision medicine are also among the factors that propel the demand for NGS services.

Market Highlight

• North America had a market share of 45% and was the market leader in the next generation sequencing services market in 2025.

• The Asia Pacific is expected to grow at the highest CAGR during the years 2026-2035.

• By service type, the human genome sequencing services segment held the largest market share of over 30% in 2025.

• By end use, the universities & other research entities segment captures the largest market share of over 50% in 2025.

Significant Growth Factors

The next generation sequencing services market trends present significant growth opportunities due to several factors:

• Growing Need for Bioinformatics/Data Analysis: Among the driving factors of the NGS services market, the demand for bioinformatics and data analysis is the strongest since NGS technologies generate large and complex genomic datasets that must then be decoded by using the advanced computational tools and the researchers' specialized knowledge for the right interpretation. The majority of research institutions, hospitals, and biopharmaceutical companies do not have either the internal bioinformatics infrastructure or the skilled workforce; hence, they have to outsource sequencing along with data processing, variant analysis, and clinical interpretation as a package. The more precise medicine, oncology, and population genomics fields are able to exploit the applications, the higher the demand for comprehensive NGS services that integrate wet-lab sequencing with powerful bioinformatics solutions, thus accelerating the market growth.

• Falling Cost of Sequencing & Better Platforms: The decreasing costs of sequencing along with the advancements in sequencing platforms are the major contributors to the growing Next Generation Sequencing (NGS) services industry where technology has truly reduced to a greater extent the costs per sample for sequencing while, at the same time, enhancing the speed, accuracy, and throughput. On top of that, the instruments have become even more powerful, the automation is more widespread, and the reagents are better optimized so that large-scale analysis of DNA is now economically supported to a greater extent than the usual customer base, such as the smaller research labs, hospitals, and biotech companies. Companies are then likely to give out the sequencing task to external service providers instead of spending money on the costly infrastructure in-house, thus increasing the demand for specialized NGS service providers directly and supporting market evolution.

What are the Major Advances Changing the Next Generation Sequencing Services Market Today?

• Integration of AI and Advanced Analytics: The convergence of artificial intelligence (AI) and advanced analytics has made a significant impact in the NGS services market by majorly improving the speed, accuracy, and scalability of genomic data interpretation. The use of AI and machine learning algorithms for variant calling, pattern recognition, quality control, and clinical interpretation has become more frequent. This usage has reduced not only the possibility of human error but also the time required for manual analysis. The service providers can, therefore, manage and analyze large and complex sequencing datasets in a more efficient way even if the customer side has limited bioinformatics expertise. The adoption of NGS is likely to expand in precision medicine, oncology, and population genomics, which means that the AI-driven analytics would provide faster turnaround times and more actionable insights. This, in turn, would make the integrated sequencing and data analysis services more appealing and would contribute to the overall market growth acceleration. For instance, in October 2025, Illumina, Inc., made public the start of a new business called BioInsight, which is an extension of Illumina and was created to satisfy the market's need for deeper biologic insights. The pharmaceutical industry, as well as researchers, has come to this point because they require access to and also need to be able to interpret very large-scale multiomic data. BioInsight, by pooling together all of Illumina's strengths in sequencing, data analysis, software, and AI, will provide its customers and partners with the means to enhance drug target identification, biological pathway understanding, novel disease mechanism discovery, and even the generation of the next biological insights. This action is in line with Illumina's vision of being a key player in the market with their new cutting-edge solutions for research and health care and also contributing to the long-term, sustainable growth of the company.

• Higher Throughput and Faster Platforms: The major breakthrough in the next-generation sequencing services market is that higher throughput and faster sequencing platforms are the starting point of this trend. The next generation sequencing technology and highly accurate methods make it possible for the modern instruments to finish processing a huge number of samples within a very short time. The combination of improvements in sequencing chemistry, automated systems, and instrument design has led to a massive increase in the output of data per run and a significant decrease in the turnaround time, making it easier and more economical to carry out large-scale projects like population genomics, oncology profiling, and clinical trials. The improvements mentioned above enable service providers to take on large volumes of samples, deliver them within clinical timelines, and charge very competitive prices, which is a scenario where research institutions, hospitals, and biopharmaceutical companies tend to outsource the sequencing activity rather than invest in the development of their own in-house capability.

Category Wise Insights

By Service Type

Why Human Genome Sequencing Services Lead the Market?

The human genome sequencing services segment held the largest market share of over 30% in 2025. Human genome sequencing services allow one to assess the genetic makeup of a person, thereby offering answers for personalized medicine, biomarker discovery, cancer-carrying gene information, and pharmacogenomics. As an example, GENEWIZ, Inc. uses the Illumina HiSeq X Ten sequencing platform and provides genome sequencing services that range from germline variant detection, somatic variation, whole-genome resequencing, and de novo genome assembly to structural variant discovery, thus boosting value creation in the market segment.

The gene regulation services segment is growing at the highest CAGR over the projected period. The increase in demand for modern genomic instruments to examine the transcriptional and epigenetic mechanisms is the main reason for the rise in the market. Moreover, the use of NGS, CRISPR-based gene-editing methods, and single-cell sequencing in cancer, immunology, and rare disease research is expected to push the market further.

By End Use

Why Universities & Other Research Entities Dominates the Next Generation Sequencing Services Market?

The universities & other research entities segment captures the largest market share of over 50% in 2025. The major factors fueling the growth are the increase in genomics-based academic research and the corresponding rise in the amount of public and private research funding. Next-generation sequencing (NGS) is frequently applied in different areas of science such as basic studies, population genomics, evolutionary transcriptomics, and functional genomics in universities and non-profit research institutes, but they often have a problem that they cannot afford to buy and maintain high-end sequencing platforms and bioinformatics infrastructure. Therefore, these institutions have to depend more and more on contract NGS service providers to get access to advanced technologies, high-throughput capacity, and specialized data analysis capabilities. In addition to that, the trend of collaborative research projects, international consortia, and extensive multi-omics studies is continually pushing the demand for scalable, cost-efficient sequencing services, thereby allowing this end-user segment to enjoy continuous revenue growth.

The hospitals & clinics segment is expected to grow at the highest rate over the projected period. The primary factor behind this development is the continuous and increasing adoption of the NGS technologies and their further integration into regular clinical workflows. The escalating demand for accurate diagnostics in cancer, rare disease detection, and infectious disease management is one of the reasons why hospitals and clinics consequently have to invest in NGS testing solutions. One example is the National Public Health Laboratory (NPHL) in Kathmandu, Nepal, which has initiated offering next-generation sequencing (NGS) for breast cancer in the country. This activity allows oncologists to analyze samples at the same location, and hence, directly, it cuts the patient’s expenses by half and also leads to quicker turnaround time. This project speeds up the delivery of diagnostic results, which, in turn, leads to the start of treatment, and the NPHL is also getting ready to offer screening for genomics and leukemia as well as other cancers. The presence of better facilities, the increasing number of medical personnel that are familiar with genomic medicine, and the growing acceptance of genetic testing by insurance companies are factors that are making NGS services a staple in clinical practice.

Report Scope

Regional Analysis

How Big is the North America Next Generation Sequencing Services Market Size?

Its market size, in terms of North America next generation sequencing services, is projected to be USD 3.1 billion in 2025 with a growth of about USD 20.0 billion in 2035 with a CAGR of 20.5% between 2026 and 2035.

Why did North America Dominate the Next Generation Sequencing Services Market in 2025?

In 2025, North America will dominate the global market with an estimated market share of 45%. The rise of the region is primarily attributed to the high-quality healthcare systems in place, the widespread adoption of precision medicine, and the strong financial backing for genomics research. The U.S., in particular, is the largest market for the technology, mainly because of the widespread adoption of NGS for the diagnosis and treatment of cancers, as well as for the detection of rare diseases and the monitoring of infectious outbreaks in hospitals, diagnostic labs, and research institutions. There has been a considerable amount of money invested in genomics and population health projects by both the public and private sectors; the National Institutes of Health is one of the organizations that provide support for such investments. It has been a regulatory win-win situation for the NGS-based tests with the FDA supervising the processes. The presence of major biotechnology companies, pharmaceutical firms, and well-known NGS service providers makes North America’s revenue growth through strong demand for high-throughput sequencing and advanced bioinformatics services continuous.

U.S. Next Generation Sequencing Services Market Trends

In the North American region, the US leads the industry expansion over the projected period. The presence of major players and their service launches is expected to drive the market growth. For instance, in January 2025, Illumina made a spectacular announcement about the creation of a new genomic alteration database called the Billion Cell Atlas, which will be of great help in drug target discovery and validation processes along with AI modeling for drug discovery. The first iteration of this tool, which is intended for the comprehension of disease biology, was presented at the JPM Healthcare conference in San Francisco, and it is projected to cover an astonishing five billion cells in three years. The three pharmaceutical giants AstraZeneca, MSD, and Eli Lilly have partnered with Illumina in the creation of this resource.

Why is Asia Pacific Experiencing the Fastest Growth in the Next Generation Sequencing Services Market?

Asia Pacific is growing at the highest CAGR over the analysis period. The main factors behind the market growth of Asia Pacific NGS services are the extension of the healthcare infrastructure, rising genomic research investments, and, moreover, the wider acceptance of precision medicine in the region of Asia Pacific. China, India, Japan, South Korea, and Australia are the countries that are significantly increasing their funds for genomic research, carrying out population-scale sequencing projects, and surveillance of infectious diseases, which in turn is increasing the demand for the outsourced NGS services.

The increasing incidences of cancer and genetic disorders, together with better access to advanced diagnostic technologies, are giving a push to the hospitals and research institutions to go for NGS-based testing without investing in the costly in-house platforms. Also, the existence of a large pool of patients, the affordability of the research, and the availability of the local biotechnology and pharmaceutical industries are the factors that are making the global service providers set up their regional facilities and form partnerships. Finally, the factors mentioned above, academic–industry collaborations, and government support all together are the drivers for the strong revenue growth of the NGS services market in Asia Pacific.

China Next Generation Sequencing Services Market Trends

China is growing at the fastest rate over the projected period. The global market is looking at China with a rising importance of its position mainly because of the government's strong support for genomics, rapid technological advancements, and the large patient pool. NGS services are rapidly becoming the standard, thus indirectly increasing the demand for precision medicine and early disease detection. Technology giants from the West are going to the East to partner not just to be able to offer more, but also to be able to fight for a place in the global market. One such noteworthy alliance is the one between Gene Solutions and Shenzhen USK Bioscience for the purpose of setting up a next-Gen sequencing lab in southern China in June 2025, which is a very strategically located part of the country. The partnership is aiming at the creation of a new era in personalized oncology care in the region by fusing Gene Solutions’ NGS know-how with USK’s diagnostics, thus enabling AI-driven methods to detect cancer and monitor the clearing of molecular residual disease more effectively.

Why is Europe is growing at a significant rate in the Next Generation Sequencing Services Market?

Europe holds the substantial market share over the projected period. Among the influential factors that accelerate the market's expansion, one might highlight the excellent regulatory measures, extensive funding for research, and the open and collaborative environment between the two sectors with the scientific community and industry. For instance, in May 2025, the company called n6 not only took a major step towards becoming known in Europe by its partnerships with distributors in the Nordic countries, Switzerland, and Central and Eastern Europe but also made it easier and more efficient for scientists to support the NGS workflows through the new distributors. The UK and Germany are quite fast among the countries in terms of NGS and its application in clinical and research areas. It is mainly the EU-wide initiatives that are supportive of personalized medicine and data sharing across borders that have allowed the region to carry out extensive genomic studies and population health research.

UK Next Generation Sequencing Services Market Trends

UK holds the dominant position in the Europe market. The UK is a major player in the European NGS services market, mainly because of the proper utilization of government support and the Genomics England project initiative. The National Health Service is directing greater attention to the application of genomics in routine care, chiefly in the categories of cancer and rare diseases, thus resulting in a higher NGS service demand. Furthermore, there is a strong collaboration between researchers, and the UK has excellent technical infrastructure that all work together as favorable factors in the area of population-scale sequencing. For instance, Azenta Life Sciences, in May 2024, opened a new Genomics Laboratory in Oxford, UK, providing next-generation sequencing services for research in diabetes, infectious diseases, and Alzheimer's, along with fast sample collection and excellent bioinformatics support as part of the package.

Why is the Middle East & Africa Region is growing rapidly in the Next Generation Sequencing Services?

The MEA region is growing at a steady rate over the projected period. The increase in the market can be attributed to the maturing investments in the infrastructures of the healthcare sector, the amplifying genomics research initiatives, and the developing awareness of precision medicine. Nations in the Middle East, especially the Gulf Cooperation Council (GCC) states, are laying out money for national genomics programs, rare disease research, and cancer diagnostics, hence increasing the need for outsourced NGS services. In Africa, Support of international partnerships and global health organizations has a great impact on NGS use increase for infectious disease monitoring, population genomics, and public health research; thus, making a contribution to the market growth.

UAE Next Generation Sequencing Services Market Trends

UAE is growing at the highest CAGR during the forecast period. The increase is backed by substantial investments from the government in healthcare modernization, genomics research, and precision medicine initiatives. The UAE is pushing for advanced genetic testing for early disease detection, rare disease diagnosis, oncology, and preventive healthcare, thus creating a greater dependence on outsourced NGS services because of the prohibitive cost and not-so-simple-to-set-up technicality involved in in-house sequencing infrastructure. National genomics and population health programs, together with the opening up of hospitals, research centers, and diagnostic laboratories with a lot of funds, are in place, and even more advanced sequencing and bioinformatics services are required to meet the demand.

Top Players in the Next Generation Sequencing Services Market and Their Offerings

• Illumina Inc.

• Thermo Fisher Scientific

• Oxford Nanopore Technologies

• Pacific Biosciences of California Inc.

• QIAGEN N.V.

• Genedata

• Roche Sequencing Solutions

• Agilent Technologies

• PerkinElmer Inc.

• Bio-Rad Laboratories Inc.

• BGI Group

• Genomics PLC

• MGI Tech

• Roche NimbleGen

• Macrogen Inc.

• Novogene Corporation

• GATC Biotech AG

• BaseClear B.V.

• Dovetail Genomics

• Fasteris SA

• Others

Key Developments

Next generation sequencing services market has experienced considerable changes in the last two years as the market players are trying to diversify their technological aspects and develop product portfolios using strategic approaches.

• In February 2025, Roche exposed its own unique, revolutionary technology of genetic sequencing through expansion (SBX), positioning it at the top of the next-generation sequencing row. The power of the SBX reaction together with an excellent sensor module provides the ultra-fast, high-throughput sequencing that is easily modifiable and can be increased for various applications. The next-generation sequencing technique gives thorough genetic, genomic, and cellular biological insights. Its ability to provide information on the functions and relationships of genes has been acknowledged, and it is indispensable in revealing the complexities of diseases such as cancer, immune disorders, and neurodegenerative conditions, where the involvement of hundreds or even thousands of genes affects the process of the disease. (https://www.roche.com/media/releases/med-cor-2025-02-20)

These strategic measures have enabled the companies to reinforce their competitive positions, increase the product line, boost their technological competencies and also seize growth opportunities in the fast-growing next generation sequencing services market.

The Next Generation Sequencing Services Market is segmented as follows:

By Service Type

• Human Genome Sequencing Services

• Microbial Genome-based Sequencing Services

• Single Cell Sequencing Services

• Gene Regulation Services

• Animal & Plant Sequencing Services

• Other Sequencing Services

By Workflow

• Pre-sequencing

• Data Analysis

• Sequencing

By End Use

• Universities & Other Research Entities

• Pharma & Biotech Entities

• Hospitals & Clinics

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America